Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

Draft guidance: 1

Draft guidance (downloadable version) (PDF 254 KB)

Draft guidance (online commenting)

Committee papers (PDF 8.38 MB)

Public committee slides (PDF 1.17 MB)

Final scope (PDF 219 KB)

Final stakeholder list (PDF 185 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 242 KB)

Draft scope post referral (PDF 231 KB)